99 related articles for article (PubMed ID: 21053367)
41. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
[TBL] [Abstract][Full Text] [Related]
42. A CDKN2A mutation in familial melanoma that abrogates binding of p16INK4a to CDK4 but not CDK6.
Jones R; Ruas M; Gregory F; Moulin S; Delia D; Manoukian S; Rowe J; Brookes S; Peters G
Cancer Res; 2007 Oct; 67(19):9134-41. PubMed ID: 17909018
[TBL] [Abstract][Full Text] [Related]
43. Tumor suppressor p16INK4a controls oncogenic K-Ras function in human pancreatic cancer cells.
Rabien A; Sanchez-Ruderisch H; Schulz P; Otto N; Wimmel A; Wiedenmann B; Detjen KM
Cancer Sci; 2012 Feb; 103(2):169-75. PubMed ID: 22049925
[TBL] [Abstract][Full Text] [Related]
44. Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth.
Williams RT; Barnhill LM; Kuo HH; Lin WD; Batova A; Yu AL; Diccianni MB
PLoS One; 2014; 9(2):e88219. PubMed ID: 24505435
[TBL] [Abstract][Full Text] [Related]
45. Dissection of protein-protein interaction and CDK4 inhibition in the oncogenic versus tumor suppressing functions of gankyrin and P16.
Mahajan A; Guo Y; Yuan C; Weghorst CM; Tsai MD; Li J
J Mol Biol; 2007 Nov; 373(4):990-1005. PubMed ID: 17881001
[TBL] [Abstract][Full Text] [Related]
46. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
[No Abstract] [Full Text] [Related]
47. The cyclin-dependent kinase inhibitor p16INK4a physically interacts with transcription factor Sp1 and cyclin-dependent kinase 4 to transactivate microRNA-141 and microRNA-146b-5p spontaneously and in response to ultraviolet light-induced DNA damage.
Al-Khalaf HH; Mohideen P; Nallar SC; Kalvakolanu DV; Aboussekhra A
J Biol Chem; 2013 Dec; 288(49):35511-25. PubMed ID: 24163379
[TBL] [Abstract][Full Text] [Related]
48. CDK4, CDK6, cyclin D1, p16(INK4a) and EGFR expression in glioblastoma with a primitive neuronal component.
Xu G; Li JY
J Neurooncol; 2018 Feb; 136(3):445-452. PubMed ID: 29150788
[TBL] [Abstract][Full Text] [Related]
49. p16INK4a-induced senescence is disabled by melanoma-associated mutations.
Haferkamp S; Becker TM; Scurr LL; Kefford RF; Rizos H
Aging Cell; 2008 Oct; 7(5):733-45. PubMed ID: 18843795
[TBL] [Abstract][Full Text] [Related]
50. CDK4/6 and IGF1 receptor inhibitors synergize to suppress the growth of p16INK4A-deficient pancreatic cancers.
Heilmann AM; Perera RM; Ecker V; Nicolay BN; Bardeesy N; Benes CH; Dyson NJ
Cancer Res; 2014 Jul; 74(14):3947-58. PubMed ID: 24986516
[TBL] [Abstract][Full Text] [Related]
51. Mammalian target of rapamycin complex 1 signaling opposes the effects of anchorage loss, leading to activation of Cdk4 and Cdc6 stabilization.
Arakawa-Takeuchi S; Kobayashi K; Park JH; Uranbileg B; Yamamoto H; Jinno S; Okayama H
FEBS Lett; 2010 Jul; 584(13):2779-85. PubMed ID: 20466002
[TBL] [Abstract][Full Text] [Related]
52. The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments.
Witkiewicz AK; Knudsen KE; Dicker AP; Knudsen ES
Cell Cycle; 2011 Aug; 10(15):2497-503. PubMed ID: 21775818
[TBL] [Abstract][Full Text] [Related]
53. A murine mesenchymal stem cell model for initiating events in osteosarcomagenesis points to CDK4/CDK6 inhibition as a therapeutic target.
Franceschini N; Gaeta R; Krimpenfort P; Briaire-de Bruijn I; Kruisselbrink AB; Szuhai K; Palubeckaitė I; Cleton-Jansen AM; Bovée JVMG
Lab Invest; 2022 Apr; 102(4):391-400. PubMed ID: 34921235
[TBL] [Abstract][Full Text] [Related]
54. Suppression of PRMT6-mediated arginine methylation of p16 protein potentiates its ability to arrest A549 cell proliferation.
Wang X; Huang Y; Zhao J; Zhang Y; Lu J; Huang B
Int J Biochem Cell Biol; 2012 Dec; 44(12):2333-41. PubMed ID: 23032699
[TBL] [Abstract][Full Text] [Related]
55. Structural consequences of tumor-derived mutations in p16INK4a probed by limited proteolysis.
Zhang B; Peng ZY
Biochemistry; 2002 May; 41(20):6293-302. PubMed ID: 12009890
[TBL] [Abstract][Full Text] [Related]
56. Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics.
Kato S; Schwaederle M; Daniels GA; Piccioni D; Kesari S; Bazhenova L; Shimabukuro K; Parker BA; Fanta P; Kurzrock R
Cell Cycle; 2015; 14(8):1252-9. PubMed ID: 25695927
[TBL] [Abstract][Full Text] [Related]
57. Reversible cell cycle inhibition and premature aging features imposed by conditional expression of p16Ink4a.
Boquoi A; Arora S; Chen T; Litwin S; Koh J; Enders GH
Aging Cell; 2015 Feb; 14(1):139-47. PubMed ID: 25481981
[TBL] [Abstract][Full Text] [Related]
58. GRIM-19 and p16(INK4a) synergistically regulate cell cycle progression and E2F1-responsive gene expression.
Sun P; Nallar SC; Raha A; Kalakonda S; Velalar CN; Reddy SP; Kalvakolanu DV
J Biol Chem; 2010 Sep; 285(36):27545-52. PubMed ID: 20522552
[TBL] [Abstract][Full Text] [Related]
59. The interplay between p16 serine phosphorylation and arginine methylation determines its function in modulating cellular apoptosis and senescence.
Lu Y; Ma W; Li Z; Lu J; Wang X
Sci Rep; 2017 Jan; 7():41390. PubMed ID: 28120917
[TBL] [Abstract][Full Text] [Related]
60. Tumor suppressor p16(INK4a) inhibits cancer cell growth by downregulating eEF1A2 through a direct interaction.
Lee MH; Choi BY; Cho YY; Lee SY; Huang Z; Kundu JK; Kim MO; Kim DJ; Bode AM; Surh YJ; Dong Z
J Cell Sci; 2013 Apr; 126(Pt 8):1744-52. PubMed ID: 23444377
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
